vida: extract claims from 2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1

- Source: inbox/queue/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/food-noise-quiet-narrative-reframes-glp1-anhedonia-as-liberation.md

@@ -10,14 +10,17 @@ agent: vida
 sourced_from: health/2026-05-05-ozempic-personality-anhedonia-glp1-dopamine.md
 scope: structural
 sourcer: Multiple (Washington Post, KTLA, Washington Times)
-supports:
+supports: ["GLP-1 anhedonia mechanism undermines social engagement and meaning as non-clinical health determinants even while treating metabolic disease"]
-- GLP-1 anhedonia mechanism undermines social engagement and meaning as non-clinical health determinants even while treating metabolic disease
+reweave_edges: ["GLP-1 anhedonia mechanism undermines social engagement and meaning as non-clinical health determinants even while treating metabolic disease|supports|2026-05-06"]
-reweave_edges:
+related: ["glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "food-noise-quiet-narrative-reframes-glp1-anhedonia-as-liberation", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant"]
-- GLP-1 anhedonia mechanism undermines social engagement and meaning as non-clinical health determinants even while treating metabolic disease|supports|2026-05-06
-related:
-- glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
 ---
 
 # Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm
 
 The 'Ozempic personality' phenomenon reveals a narrative framing problem: patients widely report 'food noise quiet' as a positive liberation from obsessive food thoughts, while the same dopaminergic suppression mechanism causes reduced interest in social activities, sex, music, and pleasure generally. The cultural positive reinforcement for 'food noise quiet' may be delaying recognition of the broader anhedonia risk. This is a narrative infrastructure problem where the same pharmacological mechanism produces both a culturally celebrated benefit (freedom from food obsession) and a harm (emotional flattening and reduced social engagement), but the positive framing dominates early adoption discourse. Clinicians describe this as 'mild anhedonia from dampening of brain's dopamine receptors' but patients frame the food-specific effects as liberation. The divergence between expert concern and patient celebration suggests the cultural narrative is shaping how the harm is perceived and whether it's recognized at all. No validated clinical scale exists yet to measure this effect, and the FDA removed suicidality warnings in 2026 rather than adding anhedonia warnings, indicating regulatory bodies are not tracking this risk despite clinical pattern recognition.
+
+## Extending Evidence
+
+**Source:** Washington Post, April 2026
+
+The Washington Post investigation documents that the 'food noise silence' narrative may mask broader anhedonia: patients report diminished enjoyment not just of food but of 'social activities, music, sex, and daily pleasures.' The cultural framing as 'liberation' from food obsession may delay recognition of clinically significant hedonic blunting.

domains/health/glp1-anhedonia-absent-from-labels-despite-54k-trial-participants.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: The systematic absence of anhedonia from regulatory labeling represents a measurement gap rather than evidence of absence, as clinical trials did not deploy validated hedonic assessment instruments
+confidence: experimental
+source: Washington Post, April 2026; FDA labeling review
+created: 2026-05-06
+title: Anhedonia is absent from all GLP-1 adverse event labels despite 54,000+ trial participants because trials were not designed to measure hedonic outcomes
+agent: vida
+sourced_from: health/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1.md
+scope: structural
+sourcer: Washington Post Health
+supports: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge"]
+related: ["fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm", "clinical-ai-safety-gap-is-doubly-structural-with-no-pre-deployment-requirements-and-no-post-market-surveillance", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible"]
+---
+
+# Anhedonia is absent from all GLP-1 adverse event labels despite 54,000+ trial participants because trials were not designed to measure hedonic outcomes
+
+The drug has been studied in 54,000+ trial participants, yet anhedonia is NOT currently listed as an adverse drug reaction or warning in any GLP-1 label. Doctors say 'reports of anhedonia are not widespread' but cases are accumulating in clinical practice. This represents a systematic regulatory oversight: the absence from labels does not reflect evidence of safety, but rather the absence of measurement. The article notes that trials were not designed to capture hedonic outcomes — no mention of validated clinical instruments like SHAPS (Snaith-Hamilton Pleasure Scale) being deployed in GLP-1 prescribing practice. The article 'describes a clinical phenomenon without mentioning any systematic measurement tool, suggesting the field has not yet operationalized this as a monitorable adverse effect.' This creates a structural detection gap: anhedonia can only be detected through systematic assessment using validated instruments, but such assessment was not part of trial protocols. The 100-case compilation represents post-market surveillance capturing what pre-market trials missed due to measurement design, not because the effect was absent.

domains/health/glp1-anhedonia-dose-dependent-reversible-weeks.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Clinical case series shows rapid reversal of broad emotional blunting when GLP-1 dose is reduced, with one documented case recovering hedonic capacity within two weeks of reducing tirzepatide from 15mg to 12.5mg weekly
+confidence: experimental
+source: Washington Post, compilation of ~100 cases from multiple institutions (unpublished), April 2026
+created: 2026-05-06
+title: GLP-1-induced anhedonia is dose-dependent and resolves within weeks of dose reduction in most cases, suggesting tonic receptor occupancy rather than permanent neurological change
+agent: vida
+sourced_from: health/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1.md
+scope: causal
+sourcer: Washington Post Health
+supports: ["glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring"]
+related: ["glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant"]
+---
+
+# GLP-1-induced anhedonia is dose-dependent and resolves within weeks of dose reduction in most cases, suggesting tonic receptor occupancy rather than permanent neurological change
+
+Researchers at multiple institutions are compiling approximately 100 cases of GLP-1-induced anhedonia from thousands treated. The key clinical finding is rapid reversibility: one patient reduced Zepbound (tirzepatide) from 15mg to 12.5mg weekly and 'within two weeks reported feeling joy again.' Most cases 'appeared to resolve with dose reduction often as quickly as within a few weeks.' This rapid reversal timeframe suggests the mechanism is tonic receptor occupancy creating sustained dopamine suppression rather than permanent neurological adaptation. The dose-dependence is demonstrated by the specific case where a 16.7% dose reduction (15mg to 12.5mg) was sufficient to restore hedonic capacity. Some persistent cases required bupropion (Wellbutrin) — an antidepressant that enhances dopamine activity — as compensatory treatment, further supporting the dopamine suppression mechanism. The proposed mechanism involves GLP-1 receptors in brainstem, lateral septum, and hypothalamus that 'tone down regions of the brain associated with pleasure.' The rapid reversibility distinguishes this from permanent neurological change and suggests the effect is maintained only during active receptor occupancy.

domains/health/glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible.md

@@ -10,9 +10,16 @@ agent: vida
 sourced_from: health/2026-osmind-glp1-psychiatric-drugs-tonic-phasic.md
 scope: causal
 sourcer: Osmind
-related: ["glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "food-noise-quiet-narrative-reframes-glp1-anhedonia-as-liberation", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms"]
+related: ["glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "food-noise-quiet-narrative-reframes-glp1-anhedonia-as-liberation", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible"]
 ---
 
 # GLP-1-induced anhedonia is a tonic receptor occupancy phenomenon, not an inherent pharmacological property, resolving with dose reduction because natural GLP-1 is phasic
 
 Natural GLP-1 is phasic: it spikes after meals and degrades within 1-2 minutes due to its endogenous half-life. Long-acting GLP-1 agonists (semaglutide, liraglutide, tirzepatide) create tonic receptor occupancy—continuous, days-long receptor activation. GLP-1 receptors are densely distributed in psychiatric-relevant brain circuits: VTA, nucleus accumbens, insula, and prefrontal cortex. The drugs function as 'a brake on the reward system' by suppressing dopamine signaling through GABA neurons in the VTA. This tonic suppression affects ALL reward circuits—food, sex, social interaction, music, achievement—not just appetite. Clinical evidence: low-dose tirzepatide (0.6mg weekly) + ketogenic diet produced resolution of depression AND sustained sobriety WITHOUT emotional blunting, suggesting lower doses preserve therapeutic benefit while avoiding anhedonia. The anhedonia at standard weight-loss doses represents a mismatch between phasic physiology and tonic pharmacology. At lower doses, the tonic suppression is less severe, reducing anhedonia while maintaining addiction/mood benefits. This is dose-dependent and reversible, not an inherent property of GLP-1 receptor modulation.
+
+
+## Supporting Evidence
+
+**Source:** Washington Post, April 2026, ~100-case compilation from multiple institutions
+
+Clinical case documentation: tirzepatide dose reduction from 15mg to 12.5mg weekly resulted in hedonic capacity restoration within two weeks. Most cases resolved 'often as quickly as within a few weeks' after dose reduction. Some persistent cases required bupropion (dopamine-enhancing antidepressant) as compensatory treatment.

domains/health/glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant.md

@@ -10,22 +10,18 @@ agent: vida
 sourced_from: health/2026-05-05-ozempic-personality-anhedonia-glp1-dopamine.md
 scope: causal
 sourcer: Multiple (Washington Post, KTLA, Washington Times)
-challenges:
+challenges: ["medical-care-explains-only-10-20-percent-of-health-outcomes-because-behavioral-social-and-genetic-factors-dominate-as-four-independent-methodologies-confirm"]
-- medical-care-explains-only-10-20-percent-of-health-outcomes-because-behavioral-social-and-genetic-factors-dominate-as-four-independent-methodologies-confirm
+related: ["modernization-dismantles-family-and-community-structures-replacing-them-with-market-and-state-relationships-that-increase-individual-freedom-but-erode-psychosocial-foundations-of-wellbeing", "modernization dismantles family and community structures replacing them with market and state relationships that increase individual freedom but erode psychosocial foundations of wellbeing", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "food-noise-quiet-narrative-reframes-glp1-anhedonia-as-liberation"]
-related:
+supports: ["Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm"]
-- modernization-dismantles-family-and-community-structures-replacing-them-with-market-and-state-relationships-that-increase-individual-freedom-but-erode-psychosocial-foundations-of-wellbeing
+reweave_edges: ["Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm|supports|2026-05-06"]
-- modernization dismantles family and community structures replacing them with market and state relationships that increase individual freedom but erode psychosocial foundations of wellbeing
-- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm
-- glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation
-- hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement
-- glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible
-- glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring
-supports:
-- Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm
-reweave_edges:
-- Cultural narrative framing 'food noise quiet' as liberation delays recognition of GLP-1 dopamine suppression harm|supports|2026-05-06
 ---
 
 # GLP-1 anhedonia mechanism undermines social engagement and meaning as non-clinical health determinants even while treating metabolic disease
 
 Clinicians are reporting a pattern they call 'Ozempic personality' where GLP-1 patients experience reduced interest not just in food but in social activities, sex, music, and other pleasurable activities. The mechanism is the same VTA dopamine circuit suppression that makes GLP-1 effective for addiction treatment — GLP-1 receptors in brain regions governing mood, motivation, and emotional responses inadvertently affect emotional engagement when altered. Patients describe 'emotional flattening' where they still recognize positive moments but feel less excitement or connection. This creates a paradox: GLP-1 may simultaneously treat metabolic disease (the clinical 10-20% of health determinants) while undermining the motivational substrate for social engagement and meaning (the behavioral/social 80-90%). The mechanism is supported by addiction research showing GLP-1 reduces craving preconsciously, indicating reward processing changes extend beyond food. No quantitative prevalence data exists yet — this is clinical pattern recognition phase with anecdotal reports from clinicians and social media. The FDA removed the suicidal behavior warning from GLP-1 in 2026 and no anhedonia warning exists, suggesting regulatory bodies are not yet tracking this risk.
+
+## Extending Evidence
+
+**Source:** Washington Post, April 2026
+
+Anhedonia extends beyond food reward to 'social activities, music, sex, and daily pleasures' — symptoms align with clinical anhedonia definition: diminished enjoyment in activities that normally bring happiness. The rapid dose-reduction reversal (weeks) suggests this is a modifiable treatment parameter rather than an unavoidable trade-off.

domains/health/glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring.md

@@ -23,3 +23,10 @@ GLP-1 receptors are densely distributed in VTA, nucleus accumbens, insula, and p
 **Source:** Psychopharmacology Institute Q1 2026 Review
 
 The Psychopharmacology Institute — a CME platform for practicing psychiatrists — now covers GLP-1 receptor agonists as emerging psychiatric pharmacology in quarterly clinical reviews. This signals that professional psychiatric education is actively incorporating GLP-1 into the psychiatric medication framework, moving beyond endocrinology-only prescribing. However, the review does not provide clinical screening protocols for psychiatrists evaluating patients already prescribed GLP-1s by other providers, indicating the competency gap persists at the protocol level despite conceptual recognition.
+
+
+## Supporting Evidence
+
+**Source:** Washington Post, April 2026
+
+No validated clinical instruments (SHAPS, Snaith-Hamilton Pleasure Scale) are being deployed in GLP-1 prescribing practice despite documented anhedonia cases. The field 'has not yet operationalized this as a monitorable adverse effect' even as 100-case compilation proceeds.

inbox/archive/health/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1.md

@@ -7,10 +7,13 @@ date: 2026-04-16
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-06
 priority: high
 tags: [GLP-1, semaglutide, anhedonia, ozempic-personality, dopamine, reward, side-effects, dose-dependence, reversibility]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content